Clinical Trials Logo

Clinical Trial Summary

This project is a retrospective observational study based on the molecular characterization of a Spanish population of patients with refractory radio-iodine differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC) with advanced and / or metastatic disease undergoing systemic treatment, or under clinical observation. Three diagnostic techniques will be performed on formalin-fixed paraffin embedded (FFPE) tumor samples from the study population: immunohistochemistry (IHC), fluorescence by in situ hybridization (FISH) as well as Next-Generation Sequencing (NGS) techniques by means of DNA and RNA analysis (Ion Platform Torrent - Oncomine Focus Assay, 52 gene detection). The results of each patient will be compared in order to correlate the results of each method.


Clinical Trial Description

Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques will be carried out to identify NTRK and RET alterations. NTRK alterations will be identified using IHC techniques (NTRK over-expression), and FISH techniques (break-apart method). RET alterations will also be identified using the FISH technique (break-apart method). At the same time, DNA and RNA will be extracted for sequencing techniques using the Oncomine Focus Assay platform, including 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions, including NTRK and RET). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04970134
Study type Observational
Source Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Contact
Status Active, not recruiting
Phase
Start date June 14, 2021
Completion date March 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03636945 - Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma N/A
Withdrawn NCT01736878 - Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma Phase 2
Completed NCT06067594 - Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.
Completed NCT01424878 - Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Completed NCT02586350 - Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) Phase 2/Phase 3
Completed NCT00514046 - Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer Phase 1/Phase 2
Recruiting NCT04787328 - A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) Phase 2
Completed NCT01730638 - ImmunoTEP for Patients With Medullary Thyroid Carcinoma. Phase 1/Phase 2
Enrolling by invitation NCT01511393 - An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Terminated NCT00923247 - A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Phase 1/Phase 2
Completed NCT00880503 - Collection of Tissue Samples for Study of Multidrug Resistance
Not yet recruiting NCT06121271 - Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications Phase 2
Completed NCT03246659 - Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC Phase 1
Recruiting NCT05534594 - Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer N/A
Not yet recruiting NCT01373736 - 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Phase 3